Could a single pill replace the shot for gonorrhea?
NCT ID NCT03959527
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested a new antibiotic called zoliflodacin, taken as a single oral dose, against the standard treatment of an injection plus pills for uncomplicated gonorrhea. Over 1,000 participants were enrolled to see if the new pill works as well and is safe. If successful, it could offer a simpler, more convenient treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zoliflodacin
What this could lead to
If successful, this could provide a simple, single-dose oral treatment for gonorrhea, reducing the need for injections and helping fight antibiotic resistance.
What could go wrong
The trial is completed but results are not yet widely available. The new drug may not be as effective as current treatments, and antibiotic resistance remains a concern.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GONORRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bangrak STI Center
Bangkok, 10120, Thailand
-
Bell Flower Clinic
Indianapolis, Indiana, 46202, United States
-
Institute of HIV Research and Innovation
Bangkok, 10330, Thailand
-
Institute of Tropical Medicine
Antwerp, 2000, Belgium
-
Jefferson County Department of Health
Birmingham, Alabama, 35233, United States
-
Louisiana State University Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
Masiphumelele Research Site
Cape Town, 7975, South Africa
-
Ndlovu Research Centre
Elandsdoorn, 0470, South Africa
-
Public Health - Seattle & King County STD Clinic
Seattle, Washington, 98104, United States
-
Public Health Service (GGD) Amsterdam / STI Outpatient Clinic
Amsterdam, 1018 WT, Netherlands
-
SAMRC Botha's Hill Clinical Research Site
Bothas Hill, 3660, South Africa
-
SAMRC Tongaat Clinical Research Site
Tongaat, 4400, South Africa
-
San Francisco Department Of Public Health City Clinic
San Francisco, California, 94103, United States
-
Setshaba Research Centre
Soshanguve, 0152, South Africa
-
Silom Community Clinic
Bangkok, 10400, Thailand
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294-0006, United States
-
Wits RHI
Johannesburg, 2001, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study uses DNA to track hidden gonorrhea in partners
- Can a common antibiotic prevent STIs? new study tests two dosing strategies
- Love and safety: new study tests if relationship skills can cut HIV risk
- New study offers free STI care to black youth in the deep south
- Free sexual health Check-Ups: will they satisfy young people?
- Rio study tests antibiotic after sex to stop STIs